Showing results (1-10 of 2,196) with videos related to
Sort By:
Pageof 220
Clinical Pharmacology and Therapeutics|February 25, 2009
The Pharm.D. investigator in clinical pharmacology: supply and demandW D FiggExpert Opinion on Investigational Drugs|November 4, 2000
TNP-470: an angiogenesis inhibitor in clinical development for cancerE A Kruger, W D FiggClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assayE A Krüger, W D FiggDrug Safety|March 1, 1995
A preliminary risk-benefit assessment of paclitaxelR J Bitton, W D Figg, E ReedAngiogenesis|January 1, 1997
New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12L Masiero, W D Figg, E C KohnThe Journal of Urology|February 25, 2000
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell linesM V Blagosklonny, S C Dixon, W D FiggWorld Journal of Urology|January 1, 1996
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladderM M Walther, W D Figg, W M LinehanBiochemical Pharmacology|August 26, 1998
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependentK S Bauer, S C Dixon, W D FiggPharmacotherapy|May 1, 1996
The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostateM N Middleman, R M Lush, W D FiggClinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 15, 2015
Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responsesJ Strauss, C Alewine, W D Figg, et al.Pageof 220